ABT - Abbott Laboratories
ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.
Perpetual Ltd trimmed its position in Abbott Laboratories (NYSE: ABT) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 444,048 shares of the healthcare product maker's stock after selling 26,238 shares during the quarter. Perpetual
Abbott (ABT) closed the most recent trading day at $101.82, moving +2.23% from the previous trading session.
These companies have a long history of dividend growth.
Abbott Laboratories provides stability through a massive, diversified portfolio of diagnostics, nutrition, and medical devices. Intuitive Surgical dominates the robotic-assisted surgery market with high growth and exceptional cash reserves.
Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade. Its stock price could more than double by 2036 using a more conservative 8% growth rate.
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
These companies might bend during a downturn, but they won't break.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preserve muscle Ensure Max Protein 3-in-1 formula provides muscle support in a single daily serving to support muscle health goals—and is available in chocolate and vanilla at major U.S. retailers Muscle-supporting ingredients like creatine and HMB are moving beyond the gym and into mainstream wellness routines as more adults prioritize strength and fitness ABBOTT PARK, Ill., Oct. 7, 2026 /PRNewswire/ -- Muscle support just got simpler.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Stocks shattered records again Tuesday while oil surged, gold hit new highs, and crypto swung wildly, setting the stage for a fresh wave of analyst moves on names like Marvell, Intuitive Surgical, and NetApp that could reshape portfolios heading into the rest of the week.
Abbott (ABT) closed the most recent trading day at $98.16, moving 1.94% from the previous trading session.
Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising choice.
Park National Corp OH lessened its position in shares of Abbott Laboratories (NYSE: ABT) by 6.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,913 shares of the healthcare product maker's stock after selling 10,269 shares during
Eastern Bank trimmed its position in Abbott Laboratories (NYSE: ABT) by 14.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 56,544 shares of the healthcare product maker's stock after selling 9,287 shares during the period. Eastern Bank's holdings in Abbott Laboratories were worth $5,588,000 as
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits ABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App.
Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.